Effects of Liraglutide and Vitamin E in Fructose-Induced Metabolic Syndrome in Rats.
Pharmacology · 2017
Last updated 2026-05-28In a study on rats, liraglutide (0.3 mg/kg/day) and vitamin E (100 mg/kg/day) were given for 6 weeks to counteract health issues caused by a high-fructose diet. Both treatments alone and together improved blood sugar control, insulin resistance, fat levels, and liver health compared to untreated rats. The combination showed the most benefit, suggesting it may help prevent metabolic syndrome.
AI summary of the abstract below.
| Journal | Pharmacology, 2017 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 0.43 |
| NIH percentile | 25 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Mash, Cardiovascular Risk Reduction |
Abstract
BACKGROUND: Metabolic syndrome (MetS) is a growing worldwide health problem. However, there is yet no effective therapy for MetS. The present work investigated the effect of liraglutide, a synthetic glucagon-like peptide-1 and vitamin E on fructose-induced MetS in rats.
SUMMARY: Liraglutide (0.3 mg/kg/day) and vitamin E (100 mg/kg/day) were administered either alone or in combination with high fructose-fed male rats for 6 weeks. Fructose-fed rats developed metabolic disorders assessed by visceral fat index, serum glucose, serum insulin, homeostasis model assessment-insulin resistance and serum lipids profile and hepatic disorders assessed by liver index, serum alanine aminotransferase and aspartate aminotransferase and steatohepatitis in histopathology. This study showed that liraglutide, vitamin E and their combination significantly ameliorated the fructose-induced metabolic and hepatic disorders. Key Messages: These results indicate a potential therapeutic benefit of liraglutide and vitamin E combination in prevention of MetS. Their protective effects might rely on their antioxidant effects as well as on the inhibition of tumor necrosis factor-α.
Verbatim abstract via PubMed 27694749 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.